Are GLP-1 medications the future of weight loss? On this week’s episode, WHOOP Global Head of Human Performance Principal Scientist, Kristen Holmes, sits down with Dr. Greg Grosicki, WHOOP Senior Research Scientist, to discuss all things GLP-1 and GLP-1 Receptor Agonists (RAs). Dr. Greg Grosicki is a member of the Performance Science team at WHOOP, an accomplished IRONMAN athlete, and holds a PhD in Human Bioenergetics and a Masters Degree in Data Science. Dr. Grosicki’s background focusses on exercise physiology and aims to help people live longer and healthier in order to perform at their peak. Dr. Grosicki recently led a study at WHOOP that looked into the effects of GLP-1 RAs on heart health and responses in health behaviors.
Kristen and Dr. Grosicki discuss Dr. Grosicki’s journey to WHOOP and his research background (1:32), using exercise physiology to help people live longer and healthier (02:52), and how research at WHOOP will help you live better (06:07). Dr. Grosicki dives into the WHOOP GLP-1 study (10:54), GLP-1 medications access (20:48), and what people should expect from a GLP-1RA (23:09). Kristen and Dr. Grosicki break down GLP-1 RAs, their relationships with food addiction (24:30), Hollywood (26:16), and the idea of microdosing drugs like ozempic (27:10). The episode continues, providing an understanding for the importance of studying GLP-1 and using WHOOP as a tool for data collection (28:20), the study’s results (32:56), and identifying research bias (35:55). Kristen and Dr. Grosicki discuss the relationship of GLP-1 and cardiovascular health (39:07), the impact of exercise on cardiovascular health (40:28) and maintaining muscle tissue when using GLP-1RAs (43:42).
Read the study here:
Heart and health behavior responses to GLP-1 receptor agonists: a 12-wk study using wearable technology and causal inference
Support the show
Follow WHOOP:
www.whoop.com
Trial WHOOP for Free
Instagram
TikTok
X
Facebook
LinkedIn
Follow Will Ahmed:
Instagram
X
LinkedIn
Follow Kristen Holmes:
Instagram
LinkedIn
Follow Emily Capodilupo:
LinkedIn
